EGFR and non-small cell lung carcinoma: In addition, an acquired resistance-related genomic aberration may emerge for each treatment, as in the case of the osimertinib resistance mechanism in EGFR T790M mutation-positive non-small-cell lung cancer, suggesting that it is meaningful to perform multiple tests to assess the resistance mechanism.